Serum sickness with an elevated level of human anti-chimeric antibody following treatment with rituximab in a child with chronic immune thrombocytopenic purpura-Reference-Cited by-同舟云学术

Serum sickness with an elevated level of human anti-chimeric antibody following treatment with rituximab in a child with chronic immune thrombocytopenic purpura

Published:2009-03-24 Issue:3 Volume:89 Page:305-309
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Goto Shoko,Goto Hiroaki,Tanoshima Reo,Kato Hiromi,Takahashi Hiroyuki,Sekiguchi Osamu,Kai Sumio

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/content/pdf/10.1007/s12185-009-0269-6.pdf

Reference25 articles.

1. Stevens W, Koene H, Zwaginga JJ, Vreugdenhil G. Chronic idiopathic thrombocytopenic purpura: present strategy, guidelines and new insights. Neth J Med. 2006;64:356–63.

2. Tamminga RY, Bruin MC. Rituximab treatment for symptomatic chronic ITP. Pediatr Blood Cancer. 2006;47:714–6. doi: 10.1002/pbc.20967 .

3. Peñalver FJ, Jiménez-Yuste V, Almagro M, et al. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients. Ann Hematol. 2006;85:400–6. doi: 10.1007/s00277-006-0123-3 .

4. Panzer S. New therapeutic options for adult chronic immune thrombocytopenic purpura: a brief review. Vox Sang. 2008;94:1–5.

5. Saleh MN, Gutheil J, Moore M, et al. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Semin Oncol. 2000;27:99–103.

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rituximab therapy for intractable pemphigus: A multicenter, open‐label, single‐arm, prospective study of 20 Japanese patients;The Journal of Dermatology;2022-10-04

2. Sequential rituximab therapy sustains remission of nephrotic syndrome but carries high risk of adverse effects;Nephrology Dialysis Transplantation;2022-07-30

3. Rituximab-induced serum sickness in a girl with nephrotic syndrome;CEN Case Reports;2022-05-20

4. Case Report: Use of Obinutuzumab as an Alternative Monoclonal Anti-CD20 Antibody in a Patient With Refractory Immune Thrombocytopenia Complicated by Rituximab-Induced Serum Sickness and Anti-Rituximab Antibodies;Frontiers in Immunology;2022-04-19

5. Rituximab-induced serum sickness and anaphylaxis in a child with nephrotic syndrome;The Turkish Journal of Pediatrics;2020